About Vericel

Advanced cell therapies for sports medicine and severe burn care

#

Vision

Vericel is committed to improving the lives of patients with serious conditions by developing and manufacturing innovative cell therapies and specialty biologics.

#

Mission

Vericel is passionately committed to meeting significant patient and healthcare provider needs by providing potentially life-enhancing cell therapies to patients with serious medical conditions.

#

Values

Vericel believes in encouraging each employee to exceed the expectations of the patients we serve, their healthcare providers, and the shareholders who support our efforts.


Previous Next

Management Team

Dominick Colangelo

Dominick Colangelo

President & CEO

Nick joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development, and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly and Company, Nick held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Nick received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.

Mike Halpin

Mike Halpin

Chief Operating Officer

Mike joined Vericel in April of 2017 with over 28 years of regulatory, quality assurance, and clinical research experience with a variety of medical device, combination product, small molecule, biologic, and advanced therapy technologies. Prior to joining Vericel, Mike was with Sanofi and Genzyme Corporation; most recently as vice president, North American region regulatory head with responsibility for Sanofi Genzyme’s rare disease, immuno-inflammatory, multiple sclerosis and other business unit products. Mike has also served as vice president, regulatory affairs for Genzyme’s biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Carticel®, Epicel®, and MACI®. Prior to Genzyme, Mike held a number of regulatory, quality, and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard, and Abiomed. Mike received his master’s degree in biomedical engineering and bachelor’s degree in biochemistry from the University of Virginia.

Gerard Michel

Gerard Michel

Chief Financial Officer & Vice President of Corporate Development

Gerard joined Vericel in June of 2014 with over 25 years of experience in the pharmaceutical industry across multiple functional areas. He has considerable experience in business development, raising capital and executing successful financial transactions. Gerard was formerly Chief Financial Officer and Vice President, Corporate Development of Biodel, where he oversaw strategic development, fundraising and capital structure management, marketing efforts, investor relations, and financial reporting and internal controls. Prior to his role at Biodel, Gerard served as Chief Financial Officer and Vice President of Corporate Development of NPS Pharmaceuticals, where he led the first syndicated royalty monetization, the structure of which has been widely copied. Prior to that, Gerard was a Principal at Booz Allen and also held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Gerard holds a M.S in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester.

Dr. Jonathan Hopper, MB ChB

Dr. Jonathan Hopper, MB ChB

Chief Medical Officer

Jon Hopper is a seasoned industry executive with previous experience as a surgeon and government regulator. He qualified in medicine in the UK in 1987 and trained as an Orthopaedic and Trauma surgeon, gaining additional clinical experience in Accident and Emergency, Sports Medicine and Trauma Intensive Care. Jon became a Fellow of the Royal College of Surgeons of Edinburgh in 1992. In 1997, he joined the UK’s Senior Civil Service as a senior medical officer at the UK’s Department of Health, regulating medical device manufacturers and advising senior government officials and Ministers of State. Jon attained the degree MBA (Health Executive) from the University of Keele 2003. In 2006, Jon joined the medical device industry and moved to the USA in 2009. He has held various Global Medical Affairs and Clinical Development Executive roles for ConvaTec, Stryker, Osiris Therapeutics and Ferring Pharmaceuticals. Jon joined Vericel in August 2018 and leads the Clinical Development, Pharmacovigilance and Medical Affairs functions.

Jacquelyn Fahey Sandell

Jacquelyn Fahey Sandell

Vice President and General Counsel

Jacqui joined Vericel in 2015 with more than twenty years of experience as in-house counsel in the biotechnology and pharmaceutical industries as well as in private practice. Jacqui has considerable experience in healthcare and pharmaceutical law and regulation, corporate governance, business development, commercial business transactions, mergers and acquisitions, intellectual property, securities law and compliance. Most recently, Jacqui was Associate General Counsel for Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceuticals) and Senior Corporate Counsel for Genzyme Corporation. Prior to Genzyme she began her legal career at Shearman & Sterling in New York, London and Paris before joining Allen & Overy in Rome, specializing in mergers and acquisitions and securities law. She holds a B.A. from Duke University and a J.D., magna cum laude, from Boston University School of Law.

Heidi Hassen

Heidi Hassen

Vice President, Human Resources

Heidi joined Vericel in September of 2010 and is responsible for leading the overall administration and strategic direction of Vericel’s Human Resources function. Heidi has held HR leadership positions for over 25 years across several industries, including computer storage technology, industrial computer manufacturing, and biotechnology.  Prior to joining Vericel she was employed by Cayman Chemical, where she was responsible for the company’s global Human Resources operations and served as a fiduciary of the Cayman Chemical Retirement Savings Plan.  Prior to Cayman Chemical she led the HR organization for Xycom Automation (Pro-face America), a manufacturer of industrial PCs. She received a B.A. in Employment Relations, College of Social Science, from Michigan State University.

Board of Directors

Robert L. Zerbe, M.D.

Robert L. Zerbe, M.D.

Lead Director since October 2012
Director since January 2006

Dr. Zerbe is the CEO of QUATRx Pharmaceuticals Company, a venture-backed drug development company which he co-founded in 2000. Prior to his role at QUATRx, he held senior executive management positions with major pharmaceutical companies including Eli Lilly and Pfizer. During his tenure at Eli Lilly, his clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity, he led the clinical development programs for key products including Lipitor® and Neurontin®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine and has completed postdoctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. Dr. Zerbe currently serves on the boards of directors of one other public company, Optimer Pharmaceuticals, Inc., and two private companies, Metabolex, Inc. and Edgemont Pharmaceuticals. Dr. Zerbe’s qualifications to sit on the Board include his management positions at major pharmaceutical companies including the experience he gleaned in his clinical development roles.

Alan L. Rubino

Alan L. Rubino

Director since September 2005

Mr. Rubino has served as CEO and President of Emisphere Technologies, Inc. since September, 2012. Previously, Mr. Rubino served as the CEO and President of New American Therapeutics, CEO and President of Akrimax Pharmaceuticals, LLC and President and COO of Pharmos Corporation. Mr. Rubino has continued to expand upon a highly successful and distinguished career which included Hoffmann-LaRoche, Inc. where he was a member of the U.S. Executive and Operating Committees and a Securities and Exchange Commission (SEC) Corporate Officer. During his Roche tenure, he held key executive positions in marketing, sales, business operations, supply chain and human resource management, and was assigned executive committee roles in marketing, project management, and globalization of the worldwide pharmaceuticals business. Mr. Rubino also held senior executive positions at PDI, Inc. and Cardinal Health. He holds a B.A. in economics from Rutgers University with a minor in biology/chemistry and completed his post-graduate educational programs at the University of Lausanne and Harvard Business School. Additionally, he serves on the Boards of Sanuwave, Inc. (SANU), Genisphere LLC, and Rutgers University School of Business, Mr. Rubino’s qualifications to sit on the Board include his leadership roles in the life sciences industry in a wide range of capacities, including positions focused on business development, sales and marketing and SEC matters.

Heidi Hagen

Heidi Hagen

Director since August 2013

Heidi M. Hagen is currently the COO and co-founder of Vitruvian Networks, a technology platform company committed to scaling and digitizing cell and gene therapies through advanced software systems, manufacturing services and data analytics. Prior to co-founding Vitruvian Networks, Heidi was the Global Chief Operating Officer for SOTIO, in Prague, Czech Republic with a US office in Boston, MA. She has an extensive and proven track record in leading operations and commercializing innovative technologies. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations, where she was responsible for technical operations, among other duties. Prior to joining Dendreon, she spent ten years with Immunex Corporation where she held various positions in drug development and supply/operations management. Heidi has a B.S. in Cell and Molecular Biology, M.S. in Bioengineering, and M.B.A. from the University of Washington.

Steven Gilman

Steven Gilman

Director since January 2015

Dr. Gilman was most recently the Chairman of the board of directors and Chief Executive Officer of ContraFect Corporation, a biopharmaceutical company developing novel therapeutics for the treatment of infections caused by multi-drug resistant bacteria. He previously served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals where he led the successful development and launch of Sivextro® and Zerbaxa®. Cubist was acquired by Merck & Co. in January 2015. Prior to joining Cubist, Dr. Gilman served as chairman of the board of directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Prior to ActivBiotics, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development and has also held scientific, business and academic appointments at Wyeth, CYTOGEN Corporation, Temple Medical School and Connecticut College. Dr. Gilman currently also serves on the board of directors of Akebia Therapeutics, Momenta Pharmaceuticals, SCYNEXIS, Inc., and ContraFect Corporation. Dr. Gilman received his M.S. and Ph.D. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio. He is an author of over 60 publications and 7 U.S. patents.

Kevin McLaughlin

Kevin McLaughlin

Director since January 2015

Kevin McLaughlin is the Senior Vice President, Chief Financial Officer and Treasurer at Acceleron Pharma. He most recently served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company. He was a Co-founder of Aptius Education, Inc. and from 2007 through 2009 he worked as the Chief Operating Officer and a Director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company’s initial public offering and subsequent stock offering. Later, Mr. McLaughlin became COO, then President and CEO, while serving as a member of the Board of Directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. in business from Northeastern University and an M.B.A from Babson College.

Paul Wotton

Paul Wotton

Director since January 2015

Dr. Wotton currently serves as the President and CEO of Sigilon Inc. He served as the President and CEO of Ocata Therapeutics from July 2014, until its acquisition by Astellas Pharma US Inc. and as the Co-Chairman of the Integration Management Office at Astellas Pharma US, Inc. until May 2016. Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS) since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories, Merck, Sharp and Dohme. Dr. Wotton is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham. In 2014 he was named New Jersey Ernst & Young Entrepreneur of the Year in Life Sciences.

Dominick Colangelo

Dominick Colangelo

President & CEO

Nick joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development, and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly and Company, Nick held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Nick received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.

A history of transformation through restoration

1987

First cell therapy

Epicel®, the 1st autologous cell therapy, is introduced by BioSurface Technologies for the treatment of patients with deep dermal or full thickness burns.

1995

Transformative medicine

Genzyme, a pioneer in the development and delivery of transformative therapies for patients affected by rare and debilitating diseases acquires BioSurface Technologies and renames the company: Genzyme Tissue Repair.

1995

First for orthopedics

Carticel®, the first autologous cell therapy for the treatment of cartilage lesions in the knee is commercialized in Europe by Genzyme Tissue Repair.

1997

Restorative treatment

Carticel receives the first BLA for a cell therapy, ushering in an entirely new mode of treatment for orthopedic injuries.

1998

Streamlined delivery

MACI®, a cellular therapy similar to Carticel but delivered on a collagen membrane, is first performed in Germany.

2004

Global presence

Genzyme acquires Verigen of Germany, the developer of MACI, along with global rights to the product, securing its commitment to next generation cellular repair therapies for cartilage defects.

2011

Biologics in the spotlight

Sanofi, a top five global pharmaceutical company, acquires Genzyme in a deal worth 20 billion US dollars.

2013

First in Europe

MACI becomes the first tissue-engineered Advanced Therapy and Medicinal product approved by the European Medicines Agency.

2014

A move toward the future

Vericel, a longtime leader in adult stem cell therapies and personalized medicine acquires global rights to Carticel, Epicel and MACI making it a worldwide leader in cellular therapies.

2016

First in USA

The FDA approves MACI, the first product utilizing tissue engineering to grow cells on scaffolds using healthy cartilage from the patient’s own knee.

Tomorrow

A commitment to innovation

Vericel is proud of our pioneering role in helping to develop the cellular therapy category. Vericel will continue to innovate and deliver on the promise of treatment derived from a patient’s own regenerative cells.

Partnering with Vericel

Vericel Corporation is dedicated to the development of advanced cell therapies for the treatment of patients with severe diseases and conditions. Vericel currently markets two advanced cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous chondrocyte implant for the treatment of cartilage defects in the knee. Epicel® (cultured epidermal autografts) is a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area. At this time Vericel is seeking partners to commercialize MACI and Epicel outside of the United States. Vericel is also seeking to acquire, co-develop or in-license products which leverage either the company’s existing sports medicine and burn care commercial capabilities, or the company’s proven cell therapy development, manufacturing and commercialization capabilities.

For more information about partnering with Vericel

Contact Us >

NASDAQ: VCEL

$17.27 -0.11 (-0.63%)
Day High: $17.44
Day Low: $16.92
Volume: 496822
4:15 PM on
August 22, 2019
Copyright West LLC. Minimum 15 minutes delayed.

Company Presentation